Insider buying last 90 days
No open-market insider purchases were filed for MDGL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MDGL insider filing, plotted on the chart in Gekko.Open MDGL in Gekko
NASDAQ: MDGL
Madrigal Pharmaceuticals (MDGL) Stock Analysis & Forecast
Sep 28 close
$517.04+0.48 (+0.1%)
Gekko Brief
AI summaryThis week's attention on Madrigal Pharmaceuticals centers on a wave of analyst coverage. Goldman Sachs initiated coverage with a Buy rating and a $704.00 price target on 24 September, followed by a separate note reiterating that target on 25 September, with commentary describing the stock as undervalued. Citigroup also initiated coverage with a Buy rating and a $725 price target, noting its figure sits above the broader analyst consensus target of $678.18, which itself carries a consensus Buy rating.
MDGL closed at $517.04, essentially flat on the day, with its 50-day average at $526.27 and 200-day average at $511.83, placing the trend between the two. The GekkoIndex reads 62.2, in the Accumulation zone. Price sits 45.6% below Gekko Fair Value of $949.72. Over the past year the stock has returned 22.2%, though the past month shows a 4.9% decline, and shares trade well off their 52-week high of $615.00.
Looking ahead, Madrigal's next earnings report is set for 3 November, 35 days out and beyond a typical 20-trading-day holding window; its last report on 30 July beat estimates but the stock reacted with a 14.5% decline. Analyst sentiment remains heavily tilted toward Buy, with 13 of 14 firms rating it so and a consensus upside of 31.9%. Seasonality over this stretch has historically leaned negative, averaging -2.8% over 5 years with gains in only 1 of them. No insider, Congress, or unusual options activity appears in current windows.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Madrigal Pharmaceuticals price vs fair value
Close $517.04200-day averageGekko Fair Value $949.72
Madrigal Pharmaceuticals quick facts
- Market cap
- $11.95B
- P/E ratio
- —
- Forward P/E
- 78.1
- EPS, TTM
- −$14.01
- Revenue, TTM
- $1.28B
- Profit margin
- -25.3%
- Dividend yield
- —
- Beta
- -0.99
- Volume
- 333,653 avg 219,500
- 1-year return
- +22.2%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±9%
- 50-day average
- $526.27
- 200-day average
- $511.83
- Next earnings
- Nov 3 before open
- Shares outstanding
- 23.10M
Madrigal Pharmaceuticals swing-trade checklist
Madrigal Pharmaceuticals scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $517.04 sits between the 50-day ($526.27) and 200-day ($511.83) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
62.2, Accumulation
Reading 62.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
45.6% below
Price is 45.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.8% on average
From this point in the calendar, the next 20 trading days averaged −2.8% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Madrigal Pharmaceuticals stock chart and price history
Madrigal Pharmaceuticals closed at $517.04 on Sep 28, 2026, +22.2% over the past year, inside a 52-week range of $393.61 to $615.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.9%
- 3 months
- −1.9%
- 6 months
- +1.2%
- 1 year
- +22.2%
The full MDGL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MDGL in Gekko
Follow Madrigal Pharmaceuticals through every session
Put MDGL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MDGL in GekkoFree for 7 days. No credit card required.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals works on new medicines for conditions tied to the heart, metabolism, and liver, with a focus on drugs still moving through clinical testing rather than products already on the market. Its furthest-along candidate, resmetirom, targets the liver and works on a specific thyroid hormone receptor, and it is being studied in late-stage Phase III trials for treating non-alcoholic steatohepatitis, a liver disease often referred to as NASH.
Behind resmetirom sits a second compound, MGL-3745, kept in reserve in case it is needed to support or replace the lead candidate. Madrigal also has a partnership with Hoffmann-La Roche that spans research, development, and eventual commercialization work, linking its drug programs to a larger collaborator as they progress.
The company operates out of West Conshohocken, Pennsylvania, and its shares are listed on the NASDAQ under the ticker MDGL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- madrigalpharma.com
Madrigal Pharmaceuticals GekkoIndex: the smart money zone
Madrigal Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.2, in the Accumulation zone, up 2.1 points over five sessions.
62.2Accumulation
Up 2.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 39 | +3.2% | +10.1% | ||
| Accumulation (current zone) | 223 | +1.2% | +7.8% | ||
| Neutral | 356 | +0.3% | +0.6% | ||
| Distribution | 48 | +2.3% | +4.4% | ||
| Selling | 6 | Too few readings yet | |||
Average MDGL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the MDGL price, zone by zone.Track MDGL in Gekko
Is Madrigal Pharmaceuticals stock overvalued? Gekko Fair Value
Madrigal Pharmaceuticals trades 45.6% below Gekko Fair Value of $949.72, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Madrigal Pharmaceuticals shares are worth, recalculated every trading day.
$949.72
Gekko Fair Value, Sep 26, 2026
45.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open MDGL in Gekko
Madrigal Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Madrigal Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MDGL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MDGL, plotted on the chart in Gekko.Open MDGL in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds MDGL.
0added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Madrigal Pharmaceuticals earnings: next date and track record
Madrigal Pharmaceuticals reports on Nov 3, 2026, before the open (35 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 35 days away
- EPS estimate
- −$1.00
- Revenue estimate
- $404.7M
6 of 8reports beat the EPS estimate
±14.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | −$1.99 est −$2.55 | $364.3M est $352.1M | −14.5% |
| May 6, 2026 | −$1.38 est −$4.14 | $311.3M est $301.1M | +6.4% |
| Feb 19, 2026 | −$2.57 est $0.04 | $321.1M est $312.5M | −11.5% |
| Nov 4, 2025 | −$4.96 est −$1.99 | $287.3M est $245.0M | +15.4% |
| Aug 5, 2025 | −$1.90 est −$3.48 | $212.8M est $243.5M | +8.3% |
| May 1, 2025 | −$3.32 est −$3.79 | $137.3M est $158.9M | −5.5% |
| Feb 26, 2025 | −$2.71 est −$4.12 | $103.3M est $97.81M | +8.5% |
| Oct 31, 2024 | −$4.92 est −$6.91 | $62.18M est $92.53M | +48.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Madrigal Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Madrigal Pharmaceuticals is $682.11, +31.9% from the last close, from 14 firms rating the stock in the last 90 days.
$682.11consensus 12-month target, +31.9% from the last close
Now $517.04Avg $682.11
Low $543High $962
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Goldman Sachs | $704 | +36.2% |
| Sep 23 | Citi | $725 | +40.2% |
| Aug 4 | Wolfe Research | $605 | +17.0% |
| Aug 3 | Barclays | $962 | +86.1% |
| Jul 31 | B. Riley Securities | $670 | +29.6% |
+7.8%average 20-day move after past Accumulation readings
−2.8%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Madrigal Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Madrigal Pharmaceuticals averaged −2.8% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.3% | 1 of 5 |
| Next 10 trading days | +0.2% | 3 of 5 |
| Next 15 trading days | −1.3% | 2 of 5 |
| Next 20 trading days | −2.8% | 1 of 5 |
| Next 30 trading days | +19.0% | 4 of 5 |
For scale, MDGL’s typical 20-trading-day move in either direction is about 9%.
Madrigal Pharmaceuticals market cap and key statistics
Madrigal Pharmaceuticals’s market cap is $11.95B and revenue of $1.28B over the last twelve months.
Valuation
- Market cap
- $11.95B
- Forward P/E
- 78.1
- EPS, TTM
- −$14.01
- Gekko Fair Value
- $949.72
Trading
- Volume
- 333,653
- Avg volume, 20 days
- 219,500
- 52-week high
- $615.00
- 52-week low
- $393.61
- Shares outstanding
- 23.10M
Financials
- Revenue, TTM
- $1.28B
- Profit margin
- -25.3%
- Return on equity
- -53.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -0.99
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±9%
Madrigal Pharmaceuticals stock news this week
Coverage of Madrigal Pharmaceuticals this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
- Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman SachsMoomoo, Sep 25
- Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating By Investing.comInvesting.com Canada, Sep 24
- Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price TargetYahoo Finance, Sep 23
Madrigal Pharmaceuticals peers
Madrigal Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Madrigal Pharmaceuticals stock FAQ
What is Madrigal Pharmaceuticals’s market cap?
Madrigal Pharmaceuticals’s market cap is $11.95B at the Sep 28, 2026 close of $517.04, with 23.10M shares outstanding.
What is the Madrigal Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Madrigal Pharmaceuticals is $682.11, +31.9% from the last close. Of the 14 firms that rated the stock in the last 90 days, 13 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Madrigal Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Madrigal Pharmaceuticals is undervalued: the Sep 28, 2026 close of $517.04 is 45.6% below Gekko Fair Value of $949.72. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Madrigal Pharmaceuticals report earnings next?
Madrigal Pharmaceuticals is expected to report on Nov 3, 2026, before the market opens (35 days away). Analysts expect earnings of −$1.00 per share on revenue of $404.7M. Madrigal Pharmaceuticals beat the earnings estimate in 6 of its last 8 reports, moving 14.8% on average across the report.
What is Madrigal Pharmaceuticals’s 52-week high and low?
Madrigal Pharmaceuticals’s 52-week high is $615.00 and its 52-week low is $393.61; it closed at $517.04 on Sep 28, 2026, +22.2% over the past year.
Is Madrigal Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Madrigal Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.